Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Collaboration of Alimentiv, AcelaBio, and PharmaNest to Transform Precision Medicine and AI Digital Pathology in NASH/MASH Clinical Trials

NextEdge Admin

08 Nov 2023

2 min 43 sec

Alimentiv Inc., AcelaBio Inc., and PharmaNest Inc. have joined forces to revolutionize precision medicine and AI-enabled digital pathology solutions for Metabolic Dysfunction-Associated Steatohepatitis (MASH) clinical trials. This collaboration aims to provide a comprehensive approach to quantifying the histological effects of compounds and understanding the underlying mechanisms in MASH-targeted therapies.

The collaborative effort integrates advanced spatial transcriptomics and AI-powered digital pathology techniques, offering high throughput specialty anatomic and molecular pathology, bioinformatics, and AI powered image analysis. AcelaBio, a CAP/CLIA-certified clinical research laboratory, will conduct tissue sample analysis generating whole slide images and molecular data, aiming to identify digital pathology biomarkers within the tissue’s spatial context. For discovering novel biomarker signatures and interrogating the spatial biology of tissues, AcelaBio implemented 10X Genomics Visium Spatial Transcriptomics into its workflows.

Alimentiv’s focus on endpoint assessments and precision medicine, including bioinformatics and AI- powered digital pathology biomarker quantitation, complements this initiative. Their expertise aims to empower clinical trial sponsors, improving histological endpoints and accelerating drug development in MASH.

PharmaNest contributes its excellence in MASH digital pathology and AI analysis, providing high- resolution, single-fiber, and single-cell quantitative image analysis. Their FibroNest platform automates high-resolution quantification of fibrosis severity, aiding pathologists and enriching the effect quantification of interventions in MASH studies. This collaboration promises to enhance current histological endpoints required for interim FDA approval of therapies in MASH and allows for a comprehensive understanding of MASH pathology and the discovery of new biomarkers.

The partnership represents a significant advancement in integrating precision medicine and digital pathology for MASH clinical trials, with the goal of enhancing early drug development efficiency and delivering safe, effective treatments to patients more promptly.